- Home
- STRR vs RNAZ Comparison
STRR vs RNAZ Comparison
Compare STRR & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRR
- RNAZ
- Stock Information
- Founded
- STRR 1985
- RNAZ 2016
- Country
- STRR United States
- RNAZ United States
- Employees
- STRR N/A
- RNAZ N/A
- Industry
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- STRR Health Care
- RNAZ Health Care
- Exchange
- STRR Nasdaq
- RNAZ Nasdaq
- Market Cap
- STRR 6.3M
- RNAZ 6.1M
- IPO Year
- STRR N/A
- RNAZ 2021
- Fundamental
- Price
- STRR $2.09
- RNAZ $10.79
- Analyst Decision
- STRR Hold
- RNAZ Strong Buy
- Analyst Count
- STRR 1
- RNAZ 1
- Target Price
- STRR N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- STRR 28.4K
- RNAZ 249.9K
- Earning Date
- STRR 08-13-2025
- RNAZ 08-14-2025
- Dividend Yield
- STRR N/A
- RNAZ N/A
- EPS Growth
- STRR N/A
- RNAZ N/A
- EPS
- STRR N/A
- RNAZ N/A
- Revenue
- STRR $67,390,000.00
- RNAZ N/A
- Revenue This Year
- STRR $33.64
- RNAZ N/A
- Revenue Next Year
- STRR $22.87
- RNAZ N/A
- P/E Ratio
- STRR N/A
- RNAZ N/A
- Revenue Growth
- STRR 42.94
- RNAZ N/A
- 52 Week Low
- STRR $1.72
- RNAZ $6.15
- 52 Week High
- STRR $4.74
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- STRR 50.84
- RNAZ 51.01
- Support Level
- STRR $1.97
- RNAZ $10.45
- Resistance Level
- STRR $2.50
- RNAZ $11.75
- Average True Range (ATR)
- STRR 0.10
- RNAZ 1.05
- MACD
- STRR 0.01
- RNAZ -0.13
- Stochastic Oscillator
- STRR 25.45
- RNAZ 16.45
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.